Market Overview

UBS Steps Off HCP

Share:

UBS’ Nick Yulico downgraded the rating on HCP, Inc. (NYSE: HCP) from Buy to Neutral, with a price target of $31.

With the appreciation in the share price, Yulico believes that the stock valuation is currently “less compelling,” while sentiment on the stock is mixed.

CMS Data Suggests Headwinds

Yulico also mentioned that recent CMS data on therapy minutes suggests the possibility of additional headwinds for the company’s largest tenant, HCR ManorCare (HCRMC).

“While our FFO/AFFO estimates already reflect a 30 percent rent cut at HCRMC to help improve rent coverage, we are not convinced HCP will take this approach and see risk that this overhang lingers,” the analyst stated, while mentioning that a rent cut would be the easiest way to restore confidence in the stock.

Although HCRMC has been facing financial difficulties, Yulico pointed out that it scored high on care outcomes in the CMS Five-Star Quality Rating System.

CMS Investigation

“However, on the negative side, a good portion of its SNF assets could be in the cross-hairs of CMS regulators due to therapy minutes billed close to the high-RUGs thresholds,” Yulico noted.

CMS has asked for an investigation into the issue for the SNF industry at the U.S. level, with possible overbilling for therapy having been alleged in a DOJ complaint against HCRMC in 2015.

“One potential silver lining is that HCP screens better than the US industry average on the therapy minutes data,” the UBS report added.

Latest Ratings for HCP

DateFirmActionFromTo
Aug 2019MaintainsBuy
Jul 2019MaintainsOverweight
Jun 2019UpgradesMarket PerformOutperform

View More Analyst Ratings for HCP
View the Latest Analyst Ratings

Posted-In: Nick Yulico UBSAnalyst Color Downgrades Analyst Ratings

 

Related Articles (HCP)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
IQDowngrades
IQDowngrades21.0
COTYMaintains9.0
FNMaintains60.0
NNNMaintains57.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Peabody Troubles Could Harm Joy Global's Ability To Hit Guidance

Do You Regret Working In Finance?